---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-295491"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2022-11-30T23:59:59+00:00"
generated_at: "2026-06-21T11:27:48.468682+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics prices $15.7M public offering of 24.2M shares at $0.62/share

## Summary
- Priced 24,228,719 shares at $0.6191 per share for gross proceeds of $15.7M.
- Net proceeds expected ~$14.6M after underwriting discounts and estimated expenses.
- Underwriter granted 30-day option to purchase up to 3,634,307 additional shares.
- Proceeds to fund continued development of product candidates and for working capital.
- Offering expected to close on or about December 1, 2022.

## SEC filing metadata
- accession: 0001193125-22-295491
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2022-11-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312522295491/0001193125-22-295491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312522295491/d424988d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-295491
- JSON: https://secwatch.observer/filing/0001193125-22-295491.json
- Plain text: https://secwatch.observer/filing/0001193125-22-295491.txt

## Key facts
- Material Agreements
  Alaunos Therapeutics, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at approximately $14.6 million (effective 2022-11-29).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: approximately $14.6 million
  - Effective: 2022-11-29
  source text: On November 29, 2022, Alaunos Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), as the sole underwriter, relating to the issuance and sale in an underwritten offering (the “Offering”) of 24,228,719 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share, to the Underwriter at a price of $0.6191 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312522295491/0001193125-22-295491-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.